S&P 5007,722.60▲0.6% Nasdaq26,477.81▲1.2% Dow52,377.57▲0.0% Russell 2K2,818.87▲1.2% 10-Yr4.99%+1bp VIX17.52−0.87 WTI$100.46▼1.3% Gold$4,079.60▲1.0% EUR/USD1.113▼0.4% BTC$80,107▼1.4% Nikkei64,131▲3.1%
At close · Wed, Oct 28, 2026
Daily Market Updates.

US Markets

Home›US Markets›Equities›Eli Lilly blows past estimates, hikes sales outlook as…

Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again

Reported · Written up by our desk · Equities

Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.

← Newer storyNew study makes grim reading for NFL insurers

More like this

US MarketsMerck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
US MarketsPoundland's future hangs in the balance as chain edges towards collapse
US MarketsPutin praises Elon Musk as a ‘genius’ as Russia develops Starlink alternative
US MarketsAlphabet earnings miss reflects first real sign that AI is taking a bite out of search
US MarketsHong Kong Leader Apologizes for Deadly Apartment Building Fire

Sources

CNBC MarketsEli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
CNBC EarningsEli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.